[{"from": "human", "value": "Provide a brief overview of this molecule. [C][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][C][=Branch2][Ring2][=C][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][F][N][C][=N][C][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][Branch1][P][C][C][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring1][=Branch2][C][Branch1][C][F][F][C][C][C][C][C][Ring1][Branch1][O][C]"}, {"from": "gpt", "value": "The molecule is an orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressed tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis."}]